0001213900-26-055909
SEC filingIceCure Medical granted 180-day Nasdaq extension until November 9, 2026, to regain $1.00 minimum bid price compliance, with no immediate impact on listing or trading of ICCM shares.
IceCure Medical received a second 180-day compliance period from Nasdaq after failing to meet the $1.00 minimum bid price requirement during the first period ending May 11, 2026. This extension, until November 9, 2026, was granted based on the company's satisfaction of other Nasdaq Capital Market listing criteria, including market value of publicly held shares, and its plan to cure the deficiency, potentially through a reverse share split. Regaining compliance hinges on achieving a $1.00 closing bid price for at least 10 consecutive business days, though Nasdaq may extend this to 20 days for assurance of sustained compliance. Importantly, the ordinary shares continue trading uninterrupted on Nasdaq under 'ICCM,' mitigating short-term delisting risk for investors.